Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation Therapy Infrastructure, Social Vulnerability, and Insurance Architecture Predict Timely Postoperative Radiation Therapy After Brain Tumor Craniotomy.

Advances in radiation oncology·2026
Same author

Retrospective patient-specific intravascular brachytherapy dosimetry using optical coherence tomography imaging.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026
Same author

Phase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

In Regard to Marks et al and Mayo et al.

International journal of radiation oncology, biology, physics·2026
Same author

Impact of surgical margins and radiation therapy on survival in spinal chordoma and chondrosarcoma: a single-institution retrospective cohort study.

Journal of neurosurgery. Spine·2026
Same author

Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26.

Neuro-oncology·2025

Related Experiment Video

Updated: May 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy.

Caroline L Holloway1, Thomas F Delaney, Kaled M Alektiar

  • 1Department of Radiation Oncology, BC Cancer Agency, Vancouver Island Centre, Victoria, BC, Canada. cholloway@bccancer.bc.ca

Brachytherapy
|February 26, 2013
PubMed
Summary

Brachytherapy (BT) offers targeted radiation for soft tissue sarcoma (STS) treatment. Recommendations cover patient selection, techniques, and dose rates for optimal outcomes.

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: May 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Soft tissue sarcoma (STS) is a rare malignancy requiring multidisciplinary treatment approaches.
  • Brachytherapy (BT) is a specialized radiation technique that delivers localized radiation doses.

Purpose of the Study:

  • To provide evidence-based recommendations for the application of brachytherapy (BT) in the management of soft tissue sarcoma (STS).

Main Methods:

  • Formulation of recommendations by a panel of experts in sarcoma brachytherapy.
  • Comprehensive review of existing clinical experience and relevant scientific literature.

Main Results:

  • Indications for adjuvant BT in STS are detailed.
  • No definitive consensus exists on BT alone versus combination with external beam radiation therapy (EBRT).
  • Factors influencing modality selection include tumor grade, size, prior surgeries, and recurrence; all BT dose rates are acceptable.

Conclusions:

  • Brachytherapy (BT) is a valuable tool in the multidisciplinary treatment of STS.
  • Key advantages include precise dose distribution, reduced integral dose, and shorter treatment durations.
  • Treatment decisions should be individualized based on clinician familiarity and patient suitability.